Clarithromycin for Skin

Besides An Essential Skin Care Ingredient, Clarithromycin Can Do More!

• 2022-05-27
  

  Keeping You Healthy? Chlorine Compounds In Medicine

  In modern medicine, chlorine compounds act as a preventative measure for various infections, including pneumonia. There are three main chlorine-based antibiotics: clarithromycin, azithromycin, and doxycycline. These drugs work by killing the bacteria responsible for the condition. However, these antibiotics also contain chlorine compounds, which can cause side effects such as stomach upset and skin irritation. To minimize these side effects, it is crucial to take the medication exactly as prescribed by your doctor.
  Chlorine Compounds
• 2022-05-05
  

  FDA Approves Innovative Combination Therapy to Eradicate Helicobacter Pylori Infection

  Recently, Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Voquezna Triple Pak (Vonolaxan, Amoxicillin, Clarithromycin Triple Combination) and Voquezna Dual Pak (Vonolaxan, Amoxicillin Dual Combination) for the treatment of Helicobacter pylori infection in adults. The press release states that both combinations contain vornoxan, a "first-in-class" potassium-competitive acid blocker that is the first derived from a new drug class approved in the U.S. in more than 30 years. Innovative acid suppression therapy.
  FDA Helicobacter Pylori
• 2020-08-24
  

  India imported raw materials rose 30%

  According to the Indian pharmaceutical industry, in the first half of this year, the average price of raw materials imported by India from China rose by 20% to 30%, resulting in a 4% to 5% decline in the profit margin of domestic pharmaceutical companies. Affected by the rising prices of China's imported raw materials and intermediates, the Indian pharmaceutical industry is facing a headwind.Epidemic increases logistics costsIn the Indian import market from January to April this year, anti-infective APIs, such as tinidazole, amoxicillin, ceftriaxone, and clav avicel ), diclofenac sodium, ofloxacin, clav syloid, clotrimazole, ciprofloxacin and hormonal raw materials The prices of dexamethasone and other items increased by 24%~38% respectively. Erythromycin thiocyanate is the raw material for the preparation of erythromycin derivatives, such as azithromycin, clarithromycin and roxithromycin. Its price has been from before the COVID-19 epidemic to the present It has risen by 20%.In addition, the prices of four APIs, paracetamol, ornidazole, azithromycin and nimesulide, have increased by 62% to 189%, respectively. The price of paracetamol rose from 262 rupees/kg in January to 425 rupees/kg in April. The price of p-aminophenol (PAP), the key starting material (KSMs) for the production of paracetamol, also rose by 27%.Ashok Kumar Madan, Executive Chairman of the Indian Pharmaceutical Manufacturers Association (IDMA) pointed out: "Since the outbreak, the global demand for the antipyretic and analgesic paracetamol has been on the rise. Supply shortage coupled with demand The increase has led to a sharp increase in the price of paracetamol and its key starting material PAP. During the pandemic, European demand for paracetamol has a huge supply shortage.” The Indian pharmaceutical industry is also highly dependent on PAP supplied by China, although there are several in India. PAP manufacturers, but due to capacity constraints, it is difficult to meet downstream production needs in the short term.In addition to raw materials, the prices of isopropyl alcohol (IPA) used in hand sanitizers and solvents used in pharmaceutical production have also risen significantly. For example, the price of IPA imported from China has risen by 10% to 15%. The increasing demand for disinfectants has become one of the main reasons for the increase in IPA prices. It is estimated that the monthly amount of IPA required by the Indian pharmaceutical industry is 20,000 to 30,000 tons.Due to the implementation of strict social distancing, public and personal hygiene requirements, China's logistics costs and production costs have risen sharply, pushing the prices of raw materials to continuously increase. During the epidemic, air freight increased from US$2 per kilogram to US$5-6 per kilogram, and the average shipping cost of containers from China to India increased from US$750 to US$1200-1300. IDMA Secretary-General Dara Patel said: "In the first half of this year, the production costs of Chinese manufacturers increased due to the implementation of safety and health measures after the blockade, and the import prices of certain APIs increased by 20%~ 30%."Complementary cooperation is the general trendOn January 23 this year, in order to prevent the spread of the new crown virus, China imposed a lockdown on Wuhan and other cities in Hubei. After nearly three months of "anti-epidemic battle", China's economic activities have basically returned to normal. Starting in early March, China's exported APIs and KSMs have successively arrived in India.After a period of continued confrontation at the border between India and China, Indian pharmaceutical companies also ruled out the possibility of interruption in the supply of Chinese raw materials. Although India relies on China for APIs, China also relies on pharmaceutical preparations provided by India.Sudarshan Jain, secretary-general of the Indian Pharmaceutical Federation, believes that rising prices of Chinese raw materials are affecting the profitability of pharmaceutical companies. Due to the shortage of manpower and raw materials, many pharmaceutical companies cannot operate at full capacity, so the supply of raw materials is correspondingly small. Despite the unfavorable factors of rising prices of raw materials, the pharmaceutical industry still strives to provide consumers with stable drugs.China and India, as the world’s two major producers and exporters of raw materials and generic drugs, maintain a relatively balanced pharmaceutical trade, which plays a decisive role in the stable supply of the global pharmaceutical market. Especially in the special stage of the spread of the world epidemic, various uncertain factors affecting normal production and market circulation appear or increase at any time, leading to increased costs, price increases, and supply shortages, which test the international pharmaceutical market industry chain The rational game.Pharmaceutical trade is a special economy involving the national economy and the people's livelihood, and has a significant social welfare nature. Under the tense situation of the world facing the anti-epidemic problem, the international market price fluctuations of pharmaceutical products should not be excessively intense, and the contradiction between upstream and downstream competition in the pharmaceutical industry should not be too intense. At the same time, the market attributes of most pharmaceutical products are also objective. The complementary cooperation of R&D, production and market resources in the global pharmaceutical industry is the general trend. Facts have proved that firming the strategic cooperation business philosophy of mutual benefit and win-win sharing is the only way for the international health and sustainable development of the pharmaceutical health industry.
  Indian pharmaceutical industry pharmaceutical materials
• 2020-08-05
  

  India's macrolide API: 90% imported from China

  Macrolide raw materials, as a member of antibiotics, play an important role in the raging global new coronavirus. China is the world's largest producer and exporter of macrolides, and India is the largest importer of this product. Ninety percent of India's imports of macrolide raw materials come from China.Since March this year, the Indian government has repeatedly restricted the export of various raw materials and preparations. Obviously, under the influence of low output and lagging international logistics under the epidemic, its raw materials and medicine production capacity is insufficient and cannot be self-sufficient. Data show that in 2019, my country's export volume of APIs was 10.118 million tons, a year-on-year increase of 8.83%. Among them, API products exported to India accounted for nearly 17% of China's total API exports.According to statistics from Health.com, China’s total exports of macrolide raw materials in 2019 were 4,047 tons, of which more than 50% were exported to India, with a value of 165 million US dollars; in the first half of 2020, the total export volume was about 2,079 tons, and exports to India also exceeded half. Therefore, the overall export volume has not changed much from last year, and the product is not greatly affected by the epidemic and the international environment. The main export products include erythromycin thiocyanate, azithromycin, clarithromycin, erythromycin base and roxithromycin.Conversely, from the perspective of India's import situation, the total import of macrolide raw materials in the first half of 2020 is 1,238 tons, of which 1,101 tons are imported from China, followed by about 107 tons from the United States. The quantity and value of raw materials from Chinese sources (including Hong Kong) accounted for 83% and 90% respectively.This shows the degree of dependence of India's macrolide raw materials on China and the trend of China's main export markets. In addition, India is a big country of generic drugs, and the global macrolide preparations depend on India. For example, 40% of the generic drugs in the United States come from India. Therefore, in the future, China will not only be limited to raw materials, but also develop downstream products, and the industrial chain will extend to the world.Among the erythromycin raw materials imported by India, the import volume of erythromycin thiocyanate and azithromycin both exceeded 500 tons. In recent years, the share of azithromycin has gradually increased, including the import of clarithromycin, which is a sign of the extension of the industrial chain. In the first half of this year, India's imports of azithromycin ranked first, accounting for more than half of the total.There are about 105 buyers of macrolide raw materials in India, of which the top 15 companies account for 64% of their imports. Import companies are relatively concentrated. Compared with Chinese suppliers, there are less than 30 companies, including trading companies. In recent years, Indian pharmaceutical companies are optimistic about the Chinese market and have established joint ventures in China.Anuh Pharma Ltd. is one of the largest manufacturers of macrolides and anti-tuberculosis drugs in India, as well as a major supplier of antibacterial, antimalarial and corticosteroids. As the largest importer of macrolide raw materials, Alembic Pharma established a Chinese joint venture with Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. and Adia (Shanghai) Pharma in May 2019. Shanghai Pharmaceutical Xinyi will hold 51% of the joint venture, Alembic will hold 44%, and Adia will hold 5%.In summary, in the first half of 2020, India's imports of China's macrolide APIs have remained stable. The current domestic market price has stabilized compared with the first quarter. The global new crown epidemic has not yet passed, and antibiotic raw materials have become an indispensable part. As an important export region of our country, the Indian market must not only rely on each other, but also compete and develop.
  India API China trade
• 2020-04-03
  

  These 15 changes will appear in drugstores in 2020

  3. The retail drug price should be reduced - with the expansion of national centralized purchase, up to now, more than 8200 stores, such as ordinary people, Yikang medicine, and shuyumin, have implemented the national bid winning price, and the retail price of 25 drugs is the bid winning price. Moreover, a new batch of purchased varieties with volume has been determined, involving 35 varieties such as acarbose, Azithromycin, Metformin and metronidazole. According to the requirements of the state, and so on, in the future, there will be more drugs with lower prices. At the same time, the official website of Shanghai Pharmaceutical purchase website also released the notice of price negotiation for "drugs limited to pharmacies" this year, and required that all drugs sold in the designated pharmacies (medical insurance counters) for medical insurance should be priced by the designated pharmacies for medical insurance and drug manufacturers themselves. This also marks the beginning of drug price reduction negotiations in drugstores. It is understood that the first batch of "pharmacy limited drugs" has 701, involving amoxicillin, azithromycin, Omeprazole, Banlangen, clarithromycin and many other pharmacies often sell drugs. It's worth noting that according to Shanghai medical purchase network, this is only the first batch, and so on. Next, the second batch and the third batch are not far away.
  drugstores changes